BRCA1 and cancer: Accordingly, tumors with disrupted HR or NHEJ pathways, including BRCA1/2, rely on POLQ activity for DSB repair, and are sensitive to POLQ inhibition, PARP inhibition or cancer therapies introducing DSBs (7–9).